{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:27:55Z","timestamp":1772292475867,"version":"3.50.1"},"reference-count":205,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Major advances have occurred in our understanding of the biology, immunology, and opportunities for treatment of chronic lymphocytic leukemia (CLL) in recent times. Surface antigen analysis has helped us define classical CLL and differentiate it from variants such as marginal zone leukemia, mantle cell leukemia, and prolymphocytic leukemia. An important observation has been that the B-cells in indolent types of CLL, which do not require therapy, have undergone somatic hypermutation and function as memory B-lymphocytes whereas those more likely to progress have not undergone this process.<\/jats:p><jats:p>Section I by Dr. Nicholas Chiorazzi encompasses emerging elements of the new biology of CLL and will address the types of somatic hypermutation that occur in CLL cells and their correlation with other parameters such as telomere length and ZAP70 status. In addition he addresses the concept of which cells are proliferating in CLL and how we can quantitate the proliferative thrust using novel methods. The interaction between these parameters is also explored.<\/jats:p><jats:p>Section II by Dr. Thomas Kipps focuses on immune biology and immunotherapy of CLL and discusses new animal models in CLL, which can be exploited to increase understanding of the disease and create new opportunities for testing the interaction of the CLL cells with a variety of elements of the immune system. It is obvious that immunotherapy is emerging as a major therapeutic modality in chronic lymphocytic leukemia. Dr. Kipps addresses the present understanding of the immune status of CLL and the role of passive immunotherapy with monoclonal antibodies such as rituximab, alemtuzumab, and emerging new antibodies. In addition the interaction between the CLL cells and the immune system, which has been exploited in gene therapy with transfection of CLL cells by CD40 ligand, is discussed.<\/jats:p><jats:p>In Section III, Dr. Michael Keating examines the question \u201cDo we have the tools to cure CLL?\u201d and focuses on the fact that we now have three distinct modalities, which are able to achieve high quality remissions with polymerase chain reaction (PCR) negativity for the immunoglobulin heavy chain in CLL. These modalities include initial chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, the use of alemtuzumab for marrow cytoreduction in minimal residual disease and allogeneic bone marrow transplants. The emergence of non-ablative marrow transplants in CLL has led to the broadening of the range of opportunities to treat older patients. The addition of rituximab to the chemotherapy preparative regimens appears to be a significant advance.<\/jats:p><jats:p>The combination of our increased understanding of the biology, immune status, and therapy of CLL provides for the first time the opportunity for curative strategies.<\/jats:p>","DOI":"10.1182\/asheducation-2003.1.153","type":"journal-article","created":{"date-parts":[[2003,11,24]],"date-time":"2003-11-24T22:16:55Z","timestamp":1069712215000},"page":"153-175","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["Biology and Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1182","volume":"2003","author":[{"given":"Michael J.","family":"Keating","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Chiorazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra N.","family":"Damle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanti R.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021219191643500_R1","doi-asserted-by":"crossref","unstructured":"Dameshek W. Chronic lymphocytic leukemia\u2014an accumulative disease of immunologically incompetent lymphocytes. Blood. 1967;29:Suppl:566\u2013584","DOI":"10.1182\/blood.V29.4.566.566"},{"key":"2020021219191643500_R2","doi-asserted-by":"crossref","unstructured":"Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Ann Rev Immunol. 2003;21:841\u2013894","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"2020021219191643500_R3","doi-asserted-by":"crossref","unstructured":"Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515\u20131525","DOI":"10.1172\/JCI3009"},{"key":"2020021219191643500_R4","doi-asserted-by":"crossref","unstructured":"Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235\u2013246","DOI":"10.4049\/jimmunol.158.1.235"},{"key":"2020021219191643500_R5","doi-asserted-by":"crossref","unstructured":"Hashimoto S, Dono M, Wakai M, et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med. 1995;181:1507\u20131517.","DOI":"10.1084\/jem.181.4.1507"},{"key":"2020021219191643500_R6","unstructured":"Valetto A, Ghiotto F, Fais F, et al. A subset of IgG+ B-CLL cells expresses virtually identical antigens receptors that bind similar peptides. Blood. 1998;92:431a"},{"key":"2020021219191643500_R7","unstructured":"Chiorazzi N, Ferrarini M. Immunoglobulin variable region gene characteristics and surface membrane phenotype define B-CLL subgroups with distinct clinical courses. Chronic Lymphoid Leukemias. Vol. Second edition, revised and expanded; 2001:81\u2013109"},{"key":"2020021219191643500_R8","unstructured":"Ghiotto F, Fais F, Valetto A, Dono M, Albesiano E, Allen SL, Rai KR, Nardini M, Tramontano A, Ferrarini M, Chiorazzi N. Antigen selection as a promoting factor for the evolution of chronic lymphocytic leukemia. J Clin Invest; in press"},{"key":"2020021219191643500_R9","doi-asserted-by":"crossref","unstructured":"Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262\u20132264.","DOI":"10.1182\/blood.V99.6.2262"},{"key":"2020021219191643500_R10","doi-asserted-by":"crossref","unstructured":"Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101:4952\u20134957","DOI":"10.1182\/blood-2002-11-3485"},{"key":"2020021219191643500_R11","unstructured":"Albesiano E, Messmer BT, Ghiotto F, Fais F, Ferrarini M, Chiorazzi N. Multiple examples of identical heavy and light chain Ig rearrangements support a primary role for antigen in the development of B-CLL. Blood. 2003;in press"},{"key":"2020021219191643500_R12","doi-asserted-by":"crossref","unstructured":"Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288\u2013294","DOI":"10.1016\/0167-5699(94)90009-4"},{"key":"2020021219191643500_R13","doi-asserted-by":"crossref","unstructured":"Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood. 1997;89:4153\u20134160","DOI":"10.1182\/blood.V89.11.4153"},{"key":"2020021219191643500_R14","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848\u20131854","DOI":"10.1182\/blood.V94.6.1848"},{"key":"2020021219191643500_R15","doi-asserted-by":"crossref","unstructured":"Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410\u20131416.","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"2020021219191643500_R16","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840\u20131847","DOI":"10.1182\/blood.V94.6.1840"},{"key":"2020021219191643500_R17","doi-asserted-by":"crossref","unstructured":"Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99:4087\u20134093.","DOI":"10.1182\/blood.V99.11.4087"},{"key":"2020021219191643500_R18","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639\u20131647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2020021219191643500_R19","doi-asserted-by":"crossref","unstructured":"Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625\u20131638.","DOI":"10.1084\/jem.194.11.1625"},{"key":"2020021219191643500_R20","doi-asserted-by":"crossref","unstructured":"Damle R, Batliwala F, Allen SL, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by Ig V gene mutations. Blood.2003; in press","DOI":"10.1182\/blood-2003-04-1345"},{"key":"2020021219191643500_R21","doi-asserted-by":"crossref","unstructured":"Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer. 2003;88:593\u2013598","DOI":"10.1038\/sj.bjc.6600763"},{"key":"2020021219191643500_R22","doi-asserted-by":"crossref","unstructured":"Fu SM, Winchester RJ, Feizi T, Walzer PD, Kunkel HG. Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc Natl Acad Sci U S A. 1974;71:4487\u20134490.","DOI":"10.1073\/pnas.71.11.4487"},{"key":"2020021219191643500_R23","doi-asserted-by":"crossref","unstructured":"Malisan F, Fluckiger AC, Ho S, Guret C, Banchereau J, Martinez-Valdez H. B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood. 1996;87:717\u2013724","DOI":"10.1182\/blood.V87.2.717.bloodjournal872717"},{"key":"2020021219191643500_R24","doi-asserted-by":"crossref","unstructured":"Efremov DG, Ivanovski M, Batista FD, Pozzato G, Burrone OR. IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations. J Clin Invest. 1996;98:290\u2013298","DOI":"10.1172\/JCI118792"},{"key":"2020021219191643500_R25","doi-asserted-by":"crossref","unstructured":"Fais F, Sellars B, Ghiotto F, et al. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest. 1996;98:1659\u20131666","DOI":"10.1172\/JCI118961"},{"key":"2020021219191643500_R26","doi-asserted-by":"crossref","unstructured":"Gurrieri C, McGuire P, Zan H, et al. Chronic lymphocytic leukemia B cells undergo somatic hypermutation and intraclonal immunoglobulin VHDJH gene diversification. J Exp Med. 2002;196:629\u2013639","DOI":"10.1084\/jem.20011693"},{"key":"2020021219191643500_R27","doi-asserted-by":"crossref","unstructured":"Oppezzo P, Vuillier F, Vasconcelos Y, et al. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood. 2003;101:4029\u20134032","DOI":"10.1182\/blood-2002-10-3175"},{"key":"2020021219191643500_R28","doi-asserted-by":"crossref","unstructured":"McCarthy H, Wierda WG, Barron LL, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003;101:4903\u20134908","DOI":"10.1182\/blood-2002-09-2906"},{"key":"2020021219191643500_R29","doi-asserted-by":"crossref","unstructured":"Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. Activation induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood (In press). 2003","DOI":"10.1182\/blood-2003-05-1585"},{"key":"2020021219191643500_R30","doi-asserted-by":"crossref","unstructured":"Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol. 2002;20:165\u2013196.","DOI":"10.1146\/annurev.immunol.20.090501.112049"},{"key":"2020021219191643500_R31","doi-asserted-by":"crossref","unstructured":"Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR. Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med. 1978;148:1570\u20131578","DOI":"10.1084\/jem.148.6.1570"},{"key":"2020021219191643500_R32","doi-asserted-by":"crossref","unstructured":"Totterman TH, Nilsson K, Sundstrom C. Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature. 1980;288:176\u2013178.","DOI":"10.1038\/288176a0"},{"key":"2020021219191643500_R33","doi-asserted-by":"crossref","unstructured":"Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood. 1996;88:1365\u20131374","DOI":"10.1182\/blood.V88.4.1365.bloodjournal8841365"},{"key":"2020021219191643500_R34","doi-asserted-by":"crossref","unstructured":"Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087\u20131093","DOI":"10.1182\/blood-2002-06-1822"},{"key":"2020021219191643500_R35","doi-asserted-by":"crossref","unstructured":"Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98:3050\u20133057.","DOI":"10.1182\/blood.V98.10.3050"},{"key":"2020021219191643500_R36","doi-asserted-by":"crossref","unstructured":"Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1993;85:439\u2013445.","DOI":"10.1111\/j.1365-2141.1993.tb03330.x"},{"key":"2020021219191643500_R37","doi-asserted-by":"crossref","unstructured":"Chaouchi N, Wallon C, Goujard C, et al. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood. 1996;87:1022\u20131029","DOI":"10.1182\/blood.V87.3.1022.bloodjournal8731022"},{"key":"2020021219191643500_R38","doi-asserted-by":"crossref","unstructured":"Trentin L, Cerutti A, Zambello R, et al. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood. 1996;87:3327\u20133335","DOI":"10.1182\/blood.V87.8.3327.bloodjournal8783327"},{"key":"2020021219191643500_R39","doi-asserted-by":"crossref","unstructured":"Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood. 1996;87:4382\u20134389","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382"},{"key":"2020021219191643500_R40","doi-asserted-by":"crossref","unstructured":"Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92:97\u2013103","DOI":"10.1046\/j.1365-2141.1996.00305.x"},{"key":"2020021219191643500_R41","doi-asserted-by":"crossref","unstructured":"Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell\u2019Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655\u20132663.","DOI":"10.1182\/blood.V96.8.2655"},{"key":"2020021219191643500_R42","doi-asserted-by":"crossref","unstructured":"Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res. 2000;79:157\u2013173.","DOI":"10.1016\/S0065-230X(00)79005-1"},{"key":"2020021219191643500_R43","unstructured":"Mangiola M, Cutrona G, Colombo M, et al. Mechanisms that control cell apoptosis or survival through surface Ig in B-CLL. Leuk Lymphoma. In press"},{"key":"2020021219191643500_R44","doi-asserted-by":"crossref","unstructured":"Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609\u20134614","DOI":"10.1182\/blood-2002-06-1683"},{"key":"2020021219191643500_R45","doi-asserted-by":"crossref","unstructured":"Stall AM, Farinas MC, Tarlinton DM, et al. Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals. Proc Natl Acad Sci U S A. 1988;85:7312\u20137316","DOI":"10.1073\/pnas.85.19.7312"},{"key":"2020021219191643500_R46","doi-asserted-by":"crossref","unstructured":"Viale A-C, Chies JAB, Huetz F, et al. VH-gene family dominance in aging mice. Scand J Immunol. 1994;39:184\u2013188","DOI":"10.1111\/j.1365-3083.1994.tb03358.x"},{"key":"2020021219191643500_R47","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100:635\u2013639.","DOI":"10.1182\/blood.V100.2.635"},{"key":"2020021219191643500_R48","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100:2289\u20132290","DOI":"10.1182\/blood-2002-03-0892"},{"key":"2020021219191643500_R49","unstructured":"Stilgenbauer S, Lichter P, Dohner H. Genomic aberrations in B cell chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic Lymphoid Leukemias (ed 2nd). New York: Marcel Dekker, Inc; 2001:353\u2013376"},{"key":"2020021219191643500_R50","doi-asserted-by":"crossref","unstructured":"Bentz M, Huck K, du Manoir S, et al. Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood. 1995;85:3610\u20133618","DOI":"10.1182\/blood.V85.12.3610.bloodjournal85123610"},{"key":"2020021219191643500_R51","doi-asserted-by":"crossref","unstructured":"Novak U, Oppliger Leibundgut E, Hager J, et al. A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:1787\u20131794","DOI":"10.1182\/blood.V100.5.1787.h81702001787_1787_1794"},{"key":"2020021219191643500_R52","unstructured":"Ottaggio L, Viaggi S, Zunino A, et al. Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression. Haematologica. 2003;88:769\u2013777"},{"key":"2020021219191643500_R53","doi-asserted-by":"crossref","unstructured":"Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. Cell. 2001;106:275\u2013286","DOI":"10.1016\/S0092-8674(01)00457-3"},{"key":"2020021219191643500_R54","doi-asserted-by":"crossref","unstructured":"Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404\u20131409.","DOI":"10.1182\/blood-2001-11-0066"},{"key":"2020021219191643500_R55","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341\u2013346.","DOI":"10.1038\/35085588"},{"key":"2020021219191643500_R56","doi-asserted-by":"crossref","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219\u2013234","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"2020021219191643500_R57","doi-asserted-by":"crossref","unstructured":"Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198\u2013206","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"2020021219191643500_R58","doi-asserted-by":"crossref","unstructured":"Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood. 2000;96:377\u2013379","DOI":"10.1182\/blood.V96.1.377"},{"key":"2020021219191643500_R59","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023\u20131029.","DOI":"10.1182\/blood.V99.3.1023"},{"key":"2020021219191643500_R60","doi-asserted-by":"crossref","unstructured":"Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177\u20131184.","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184"},{"key":"2020021219191643500_R61","doi-asserted-by":"crossref","unstructured":"Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764\u20131775","DOI":"10.1056\/NEJMoa023143"},{"key":"2020021219191643500_R62","doi-asserted-by":"crossref","unstructured":"Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944\u20134951","DOI":"10.1182\/blood-2002-10-3306"},{"key":"2020021219191643500_R63","doi-asserted-by":"crossref","unstructured":"Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181\u2013186.","DOI":"10.1182\/blood.V98.1.181"},{"key":"2020021219191643500_R64","doi-asserted-by":"crossref","unstructured":"Chang CC, Cleveland RP. Conversion of CD38 and\/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course. Blood. 2002;100:1106.","DOI":"10.1182\/blood-2002-04-1287"},{"key":"2020021219191643500_R65","unstructured":"Messmer D, Messmer B, Albesiano E, et al. Direct measurement of B-CLL cell production and turnover in vivo. Blood. 2002;100:169a"},{"key":"2020021219191643500_R66","doi-asserted-by":"crossref","unstructured":"Hellerstein M, Neese R. Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. Am J Physiol. 1999;276:E1146\u2013E1170","DOI":"10.1152\/ajpendo.1999.276.6.E1146"},{"key":"2020021219191643500_R67","doi-asserted-by":"crossref","unstructured":"Zupo S, Cutrona G, Mangiola M, Ferrarini M. Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood. 2002;99:2277\u20132278.","DOI":"10.1182\/blood-2001-11-0126"},{"key":"2020021219191643500_R68","doi-asserted-by":"crossref","unstructured":"Broker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic cells secrete multispecific autoantibodies. J Autoimmun. 1988;1:469\u2013481.","DOI":"10.1016\/0896-8411(88)90068-6"},{"key":"2020021219191643500_R69","doi-asserted-by":"crossref","unstructured":"Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989;169:255\u2013268","DOI":"10.1084\/jem.169.1.255"},{"key":"2020021219191643500_R70","doi-asserted-by":"crossref","unstructured":"Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood. 1990;76:562\u2013569","DOI":"10.1182\/blood.V76.3.562.562"},{"key":"2020021219191643500_R71","doi-asserted-by":"crossref","unstructured":"Silverman GJ, Goldfien RD, Chen P, et al. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J Clin Invest. 1988;82:469\u2013475","DOI":"10.1172\/JCI113620"},{"key":"2020021219191643500_R72","doi-asserted-by":"crossref","unstructured":"Pascual V, Victor K, Spellerberg M, Hamblin TJ, Stevenson FK, Capra JD. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol. 1992;149:2337\u20132344.","DOI":"10.4049\/jimmunol.149.7.2337"},{"key":"2020021219191643500_R73","doi-asserted-by":"crossref","unstructured":"Stevenson FK, Longhurst C, Chapman CJ, et al. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J Autoimmun. 1993;6:809\u2013825.","DOI":"10.1006\/jaut.1993.1066"},{"key":"2020021219191643500_R74","doi-asserted-by":"crossref","unstructured":"Adderson EE, Shackelford PG, Quinn A, et al. Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J Clin Invest. 1993;91:2734\u20132743.","DOI":"10.1172\/JCI116514"},{"key":"2020021219191643500_R75","doi-asserted-by":"crossref","unstructured":"Zhou J, Lottenbach KR, Barenkamp SJ, Lucas AH, Reason DC. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun. 2002;70:4083\u20134091","DOI":"10.1128\/IAI.70.8.4083-4091.2002"},{"key":"2020021219191643500_R76","doi-asserted-by":"crossref","unstructured":"Diaw L, Siwarski D, Coleman A, et al. Restricted immunoglobulin variable region (Ig V) gene expression accompanies secondary rearrangements of light chain Ig V genes in mouse plasmacytomas. J Exp Med. 1999;190:1405\u20131416","DOI":"10.1084\/jem.190.10.1405"},{"key":"2020021219191643500_R77","doi-asserted-by":"crossref","unstructured":"Diamond B, Scharff MD. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci U S A. 1984;81:5841\u20135844","DOI":"10.1073\/pnas.81.18.5841"},{"key":"2020021219191643500_R78","doi-asserted-by":"crossref","unstructured":"Martin F, Kearney JF. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a \u201cnatural immune memory\u201d. Immunol Rev. 2000;175:70\u201379.","DOI":"10.1111\/j.1600-065X.2000.imr017515.x"},{"key":"2020021219191643500_R79","doi-asserted-by":"crossref","unstructured":"Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99:6955\u20136960.","DOI":"10.1073\/pnas.102181599"},{"key":"2020021219191643500_R80","doi-asserted-by":"crossref","unstructured":"Maloum K, Sutton L, Baudet S, et al. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol. 2002;119:970\u2013975.","DOI":"10.1046\/j.1365-2141.2002.03956.x"},{"key":"2020021219191643500_R81","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100:2289\u20132290.","DOI":"10.1182\/blood-2002-03-0892"},{"key":"2020021219191643500_R82","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100:635\u2013639.","DOI":"10.1182\/blood.V100.2.635"},{"key":"2020021219191643500_R83","unstructured":"Lichtman MA. Essential monoclonal gammopathy. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams\u2019 Hematology. 6th ed. New York, NY: McGraw-Hill; 2000:1271\u20131277."},{"key":"2020021219191643500_R84","doi-asserted-by":"crossref","unstructured":"Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99:6955\u20136960.","DOI":"10.1073\/pnas.102181599"},{"key":"2020021219191643500_R85","doi-asserted-by":"crossref","unstructured":"Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91:12530\u201312534.","DOI":"10.1073\/pnas.91.26.12530"},{"key":"2020021219191643500_R86","doi-asserted-by":"crossref","unstructured":"Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci U S A. 1998;95:3885\u20133889.","DOI":"10.1073\/pnas.95.7.3885"},{"key":"2020021219191643500_R87","doi-asserted-by":"crossref","unstructured":"Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A. 2002;99:14392\u201314397.","DOI":"10.1073\/pnas.212410199"},{"key":"2020021219191643500_R88","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840\u20131847.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"2020021219191643500_R89","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848\u20131854.","DOI":"10.1182\/blood.V94.6.1848"},{"key":"2020021219191643500_R90","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023\u20131029.","DOI":"10.1182\/blood.V99.3.1023"},{"key":"2020021219191643500_R91","doi-asserted-by":"crossref","unstructured":"Kro\u0308ber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410\u20131416.","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"2020021219191643500_R92","doi-asserted-by":"crossref","unstructured":"Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404\u20131409.","DOI":"10.1182\/blood-2001-11-0066"},{"key":"2020021219191643500_R93","doi-asserted-by":"crossref","unstructured":"Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177\u20131184.","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184"},{"key":"2020021219191643500_R94","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002;16:993\u20131007.","DOI":"10.1038\/sj.leu.2402537"},{"key":"2020021219191643500_R95","doi-asserted-by":"crossref","unstructured":"Naylor M, Capra JD. Mutational status of Ig V(H) genes provides clinically valuable information in B-cell chronic lymphocytic leukemia. Blood. 1999;94:1837\u20131839.","DOI":"10.1182\/blood.V94.6.1837"},{"key":"2020021219191643500_R96","doi-asserted-by":"crossref","unstructured":"Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmentally restricted VH gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1989;86:5913\u20135917.","DOI":"10.1073\/pnas.86.15.5913"},{"key":"2020021219191643500_R97","doi-asserted-by":"crossref","unstructured":"Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B-cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235\u2013246.","DOI":"10.4049\/jimmunol.158.1.235"},{"key":"2020021219191643500_R98","doi-asserted-by":"crossref","unstructured":"Sasso EH, Johnson T, Kipps TJ. Expression of the Ig VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest. 1996;97:2074\u20132080.","DOI":"10.1172\/JCI118644"},{"key":"2020021219191643500_R99","doi-asserted-by":"crossref","unstructured":"Widhopf GF II, Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001;166:95\u2013102.","DOI":"10.4049\/jimmunol.166.1.95"},{"key":"2020021219191643500_R100","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639\u20131647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2020021219191643500_R101","doi-asserted-by":"crossref","unstructured":"Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625\u20131638.","DOI":"10.1084\/jem.194.11.1625"},{"key":"2020021219191643500_R102","doi-asserted-by":"crossref","unstructured":"Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609\u20134614.","DOI":"10.1182\/blood-2002-06-1683"},{"key":"2020021219191643500_R103","doi-asserted-by":"crossref","unstructured":"Taniguchi T, Kobayashi T, Kondo J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem. 1991;266:15790\u201315796.","DOI":"10.1016\/S0021-9258(18)98478-4"},{"key":"2020021219191643500_R104","doi-asserted-by":"crossref","unstructured":"Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71:649\u2013662.","DOI":"10.1016\/0092-8674(92)90598-7"},{"key":"2020021219191643500_R105","doi-asserted-by":"crossref","unstructured":"Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol. 1997;9:205\u2013212.","DOI":"10.1016\/S0955-0674(97)80064-6"},{"key":"2020021219191643500_R106","doi-asserted-by":"crossref","unstructured":"Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol. 2000;12:242\u2013249.","DOI":"10.1016\/S0952-7915(00)00083-2"},{"key":"2020021219191643500_R107","doi-asserted-by":"crossref","unstructured":"Chan AC, van Oers NS, Tran A, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol. 1994;152:4758\u20134766.","DOI":"10.4049\/jimmunol.152.10.4758"},{"key":"2020021219191643500_R108","doi-asserted-by":"crossref","unstructured":"Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood. 1995;86:1090\u20131097.","DOI":"10.1182\/blood.V86.3.1090.1090"},{"key":"2020021219191643500_R109","doi-asserted-by":"crossref","unstructured":"Lankester AC, Schijndel GM, Pakker NG, Van Oers RH, van Lier RA. Antigen receptor function in chronic lymphocytic leukemia B cells. Leuk Lymphoma. 1996;24:27\u201333.","DOI":"10.3109\/10428199609045711"},{"key":"2020021219191643500_R110","doi-asserted-by":"crossref","unstructured":"Semichon M, Merle-Beral H, Lang V, Bismuth G. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia. 1997;11:1921\u20131928.","DOI":"10.1038\/sj.leu.2400832"},{"key":"2020021219191643500_R111","doi-asserted-by":"crossref","unstructured":"Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell\u2019Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655\u20132663.","DOI":"10.1182\/blood.V96.8.2655"},{"key":"2020021219191643500_R112","doi-asserted-by":"crossref","unstructured":"Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99:1030\u20131037.","DOI":"10.1182\/blood.V99.3.1030"},{"key":"2020021219191643500_R113","doi-asserted-by":"crossref","unstructured":"Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43:461\u2013466.","DOI":"10.1080\/10428190290011921"},{"key":"2020021219191643500_R114","doi-asserted-by":"crossref","unstructured":"de la Fuente MT, Casanova B, Moyano JV, et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol. 2002;71:495\u2013502.","DOI":"10.1189\/jlb.71.3.495"},{"key":"2020021219191643500_R115","doi-asserted-by":"crossref","unstructured":"Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94:3658\u20133667.","DOI":"10.1182\/blood.V94.11.3658"},{"key":"2020021219191643500_R116","doi-asserted-by":"crossref","unstructured":"Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin\u2019s lymphoma. Exp Hematol. 2002;30:135\u2013141.","DOI":"10.1016\/S0301-472X(01)00774-3"},{"key":"2020021219191643500_R117","doi-asserted-by":"crossref","unstructured":"Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002;100:2973\u20132979.","DOI":"10.1182\/blood-2002-02-0558"},{"key":"2020021219191643500_R118","doi-asserted-by":"crossref","unstructured":"Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260\u2013263.","DOI":"10.1126\/science.285.5425.260"},{"key":"2020021219191643500_R119","doi-asserted-by":"crossref","unstructured":"Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999;65:680\u2013683.","DOI":"10.1002\/jlb.65.5.680"},{"key":"2020021219191643500_R120","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem. 1999;274:15978\u201315981.","DOI":"10.1074\/jbc.274.23.15978"},{"key":"2020021219191643500_R121","doi-asserted-by":"crossref","unstructured":"Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747\u20131756.","DOI":"10.1084\/jem.189.11.1747"},{"key":"2020021219191643500_R122","doi-asserted-by":"crossref","unstructured":"Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803\u2013843.","DOI":"10.2165\/00003495-200363080-00005"},{"key":"2020021219191643500_R123","doi-asserted-by":"crossref","unstructured":"Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody Rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002;69:129\u2013134.","DOI":"10.1034\/j.1600-0609.2002.02786.x"},{"key":"2020021219191643500_R124","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Barton JH, et al. Single-agent Rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746\u20131751.","DOI":"10.1200\/JCO.2003.09.027"},{"key":"2020021219191643500_R125","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165\u20132170.","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"2020021219191643500_R126","doi-asserted-by":"crossref","unstructured":"Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507\u20132513.","DOI":"10.1182\/blood-2002-06-1639"},{"key":"2020021219191643500_R127","doi-asserted-by":"crossref","unstructured":"Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with Rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6\u201314.","DOI":"10.1182\/blood-2002-04-1258"},{"key":"2020021219191643500_R128","doi-asserted-by":"crossref","unstructured":"Rai K, Hallek M. Future prospects for alemtuzumab (MabCampath). Med Oncol. 2002;19(suppl):S57\u2013S63.","DOI":"10.1385\/MO:19:2S:S57"},{"key":"2020021219191643500_R129","doi-asserted-by":"crossref","unstructured":"Osterborg A, Mellstedt H, Keating M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol. 2002;19(suppl):S21\u2013S26.","DOI":"10.1385\/MO:19:2S:S21"},{"key":"2020021219191643500_R130","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347:452\u2013453.","DOI":"10.1056\/NEJM200208083470619"},{"key":"2020021219191643500_R131","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29\u201335.","DOI":"10.1182\/blood.V98.1.29"},{"key":"2020021219191643500_R132","doi-asserted-by":"crossref","unstructured":"Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133\u20131141.","DOI":"10.1172\/JCI1472"},{"key":"2020021219191643500_R133","doi-asserted-by":"crossref","unstructured":"Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999;10:1375\u20131387.","DOI":"10.1089\/10430349950018049"},{"key":"2020021219191643500_R134","doi-asserted-by":"crossref","unstructured":"Loskog A, Bjorkland A, Brown MP, Korsgren O, Malmstrom PU, Totterman TH. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 2001;166:1093\u20131097.","DOI":"10.1016\/S0022-5347(05)65928-9"},{"key":"2020021219191643500_R135","doi-asserted-by":"crossref","unstructured":"Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997;90:1927\u20131933.","DOI":"10.1182\/blood.V90.5.1927"},{"key":"2020021219191643500_R136","unstructured":"Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res. 2000;60:6391\u20136395."},{"key":"2020021219191643500_R137","doi-asserted-by":"crossref","unstructured":"Nakajima A, Kodama T, Morimoto S, et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol. 1998;161:1901\u20131907.","DOI":"10.4049\/jimmunol.161.4.1901"},{"key":"2020021219191643500_R138","doi-asserted-by":"crossref","unstructured":"Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia. 2001;15:1451\u20131457.","DOI":"10.1038\/sj.leu.2402208"},{"key":"2020021219191643500_R139","doi-asserted-by":"crossref","unstructured":"Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Russak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917\u20132924.","DOI":"10.1182\/blood.V96.9.2917"},{"key":"2020021219191643500_R140","doi-asserted-by":"crossref","unstructured":"Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:3854\u20133859.","DOI":"10.1073\/pnas.022604399"},{"key":"2020021219191643500_R141","doi-asserted-by":"crossref","unstructured":"Ranheim EA, Kipps TJ. Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925\u2013935.","DOI":"10.1084\/jem.177.4.925"},{"key":"2020021219191643500_R142","doi-asserted-by":"crossref","unstructured":"Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995;161:226\u2013235.","DOI":"10.1006\/cimm.1995.1031"},{"key":"2020021219191643500_R143","doi-asserted-by":"crossref","unstructured":"Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature. 1994;367:425\u2013428.","DOI":"10.1038\/367425a0"},{"key":"2020021219191643500_R144","doi-asserted-by":"crossref","unstructured":"Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol. 1991;9:770.","DOI":"10.1200\/JCO.1991.9.5.770"},{"key":"2020021219191643500_R145","doi-asserted-by":"crossref","unstructured":"Galton DAG, Wiltshaw E, Szur L, et al. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Br J Haematol. 1961;7:73.","DOI":"10.1111\/j.1365-2141.1961.tb00321.x"},{"key":"2020021219191643500_R146","unstructured":"Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. Chronic Lymphocytic Leukemia. Recent Progress and Future Direction. New York, NY: AR Liss; 1987:253."},{"key":"2020021219191643500_R147","doi-asserted-by":"crossref","unstructured":"Binet JL, Leporrier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer. 1977;40:855.","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1"},{"key":"2020021219191643500_R148","doi-asserted-by":"crossref","unstructured":"Catovsky D, Fooks J, Richards S, et al. Prognostic factors in chronic lymphocytic leukemia: The importance of age, sex and response to treatment in survival. Br J Haematol. 1989;72:141\u2013147.","DOI":"10.1111\/j.1365-2141.1989.tb07674.x"},{"key":"2020021219191643500_R149","unstructured":"Keating MJ, Lerner S, Kantarjian H, et al. The serum \u03b22-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood. 1995;86(suppl 1):606a."},{"key":"2020021219191643500_R150","doi-asserted-by":"crossref","unstructured":"Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1997;27:523\u2013532.","DOI":"10.3109\/10428199709058320"},{"key":"2020021219191643500_R151","doi-asserted-by":"crossref","unstructured":"Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum levels of CD23 in chronic lymphocytic leukemia. Blood. 1996;88:4259\u20134264.","DOI":"10.1182\/blood.V88.11.4259.4259"},{"key":"2020021219191643500_R152","unstructured":"Damle RN, Fais F, Wasil T, et al. B-cell patients can be divided into two distinct clinical categories based on CD38 expression and IgV gene mutation status. Blood. 1998;92:431a."},{"key":"2020021219191643500_R153","unstructured":"Hamblin TJ, Davis Z, Oscier DG, et al. In chronic lymphocytic leukemias germline configuration of immunoglobulin heavy chain genes is associated with a more aggressive form of the disease. Blood. 1998;92(suppl 1):515."},{"key":"2020021219191643500_R154","doi-asserted-by":"crossref","unstructured":"Ibrahim S, Keating M, Do K-A, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181\u2013186.","DOI":"10.1182\/blood.V98.1.181"},{"key":"2020021219191643500_R155","doi-asserted-by":"crossref","unstructured":"McCarthy H, Wierda WG, Barron LL, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003;101:4903\u20134908.","DOI":"10.1182\/blood-2002-09-2906"},{"key":"2020021219191643500_R156","doi-asserted-by":"crossref","unstructured":"Oppezzo P, Vuillier F, Vasconcelos Y, et al. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood. 2003;101:4029\u20134032.","DOI":"10.1182\/blood-2002-10-3175"},{"key":"2020021219191643500_R157","doi-asserted-by":"crossref","unstructured":"Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Eng J Med. 2003;348(18):1764\u20131775.","DOI":"10.1056\/NEJMoa023143"},{"key":"2020021219191643500_R158","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639\u20131647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2020021219191643500_R159","doi-asserted-by":"crossref","unstructured":"Diehl LF, Karnell LH, Menck HR. The National Cancer data base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 1999;86:2684\u20132692.","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2684::AID-CNCR13>3.0.CO;2-V"},{"key":"2020021219191643500_R160","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Kay N, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;12:4990\u20134997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"2020021219191643500_R161","doi-asserted-by":"crossref","unstructured":"International Workshop on Chronic Lymphocytic Leukemia. Recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989;110:236.","DOI":"10.7326\/0003-4819-110-3-236"},{"key":"2020021219191643500_R162","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols from chronic lymphocytic leukemia. Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol. 1988;29:152.","DOI":"10.1002\/ajh.2830290307"},{"key":"2020021219191643500_R163","doi-asserted-by":"crossref","unstructured":"Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992;80:29\u201336.","DOI":"10.1182\/blood.V80.1.29.29"},{"key":"2020021219191643500_R164","doi-asserted-by":"crossref","unstructured":"Vuillier F, Claisse JF, Vandenvelde C, et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma. 1992;7:195\u2013204.","DOI":"10.3109\/10428199209053623"},{"key":"2020021219191643500_R165","doi-asserted-by":"crossref","unstructured":"Clavio M, Miglino M, Spriano M, et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol. 1998;61:197\u2013203.","DOI":"10.1111\/j.1600-0609.1998.tb01084.x"},{"key":"2020021219191643500_R166","doi-asserted-by":"crossref","unstructured":"Magnac C, Sutton L, Cazin B, et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther. 1999;41:13\u201318.","DOI":"10.1007\/s00282-999-0013-y"},{"key":"2020021219191643500_R167","doi-asserted-by":"crossref","unstructured":"Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998;91:2955\u20132960.","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960"},{"key":"2020021219191643500_R168","doi-asserted-by":"crossref","unstructured":"Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88:2228\u20132235.","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228"},{"key":"2020021219191643500_R169","doi-asserted-by":"crossref","unstructured":"Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93:3081\u20133087.","DOI":"10.1182\/blood.V93.9.3081"},{"key":"2020021219191643500_R170","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29\u201335.","DOI":"10.1182\/blood.V98.1.29"},{"key":"2020021219191643500_R171","doi-asserted-by":"crossref","unstructured":"Hansen MM, Anderson E, Birgens H, et al. CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia. Leuk Lymphoma. 1991;5:97.","DOI":"10.3109\/10428199109103387"},{"key":"2020021219191643500_R172","doi-asserted-by":"crossref","unstructured":"Keating MJ, O\u2019Brien S, Lerner S, et al. Long term follow-up of patient with CLL receiving fludarabine regimens as initial therapy. Blood. 1998;92:65\u201371.","DOI":"10.1182\/blood.V92.4.1165"},{"key":"2020021219191643500_R173","doi-asserted-by":"crossref","unstructured":"Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma. 1991;5:133\u2013138.","DOI":"10.3109\/10428199109103394"},{"key":"2020021219191643500_R174","doi-asserted-by":"crossref","unstructured":"Dillman RO, Mick R, McIntryre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of cancer and leukemia group B. J Clin Oncol. 1989;7:433.","DOI":"10.1200\/JCO.1989.7.4.433"},{"key":"2020021219191643500_R175","doi-asserted-by":"crossref","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750\u20131757.","DOI":"10.1056\/NEJM200012143432402"},{"key":"2020021219191643500_R176","unstructured":"Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000;96:2723\u20132729."},{"key":"2020021219191643500_R177","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414\u20131420.","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"2020021219191643500_R178","doi-asserted-by":"crossref","unstructured":"Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71\u201375.","DOI":"10.1182\/blood.V96.1.71"},{"key":"2020021219191643500_R179","doi-asserted-by":"crossref","unstructured":"Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol. 2002;119(4):976\u2013984.","DOI":"10.1046\/j.1365-2141.2002.03959.x"},{"key":"2020021219191643500_R180","doi-asserted-by":"crossref","unstructured":"Byrd JC, Peterson BL, Morrison VL, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6\u201314.","DOI":"10.1182\/blood-2002-04-1258"},{"key":"2020021219191643500_R181","unstructured":"Keating MJ, Manshouri T, O\u2019Brien S, et al. A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia. Blood. 2003;22:569."},{"key":"2020021219191643500_R182","doi-asserted-by":"crossref","unstructured":"Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326\u20131331.","DOI":"10.1182\/blood.V98.5.1326"},{"key":"2020021219191643500_R183","doi-asserted-by":"crossref","unstructured":"Byrd JD, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153.","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"2020021219191643500_R184","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165.","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"2020021219191643500_R185","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed: results of a large international study. Blood. 2002;99:3554\u20133556.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"2020021219191643500_R186","doi-asserted-by":"crossref","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768.","DOI":"10.1182\/blood-2002-01-0159"},{"key":"2020021219191643500_R187","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u20132833.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"2020021219191643500_R188","doi-asserted-by":"crossref","unstructured":"Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic signficance. Blood. 2003;101(7):2507\u20132513.","DOI":"10.1182\/blood-2002-06-1639"},{"key":"2020021219191643500_R189","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:4261\u20134267.","DOI":"10.1200\/JCO.2002.08.674"},{"key":"2020021219191643500_R190","unstructured":"Thomas DA, O\u2019Brien S, Giles FJ, et al. Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL). Blood. 2001;98:364a."},{"key":"2020021219191643500_R191","unstructured":"Ferrajoli A, Thomas DA, Albitar M, et al. Alemtuzumab for minimal residual disease in CLL. Blood. 2003;22:569"},{"key":"2020021219191643500_R192","unstructured":"Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002;87:695\u2013700."},{"key":"2020021219191643500_R193","doi-asserted-by":"crossref","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:2453\u20132463.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2020021219191643500_R194","doi-asserted-by":"crossref","unstructured":"Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177\u2013186.","DOI":"10.1089\/cbr.1997.12.177"},{"key":"2020021219191643500_R195","unstructured":"Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin\u2019s lymphoma to apoptosis. Clin Cancer Res. 2001;7:709\u2013723."},{"key":"2020021219191643500_R196","doi-asserted-by":"crossref","unstructured":"Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383\u20133389.","DOI":"10.1182\/blood.V98.12.3383"},{"key":"2020021219191643500_R197","doi-asserted-by":"crossref","unstructured":"Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245\u20132247.","DOI":"10.1182\/blood.V99.6.2245"},{"key":"2020021219191643500_R198","unstructured":"Elter T, Borchmann P, Reiser M, et al. Development of a new, four-weekly schedule (FluCam) with concomittant application of Campath-1H and fludarabine in patients with relapsed\/refractory CLL. Blood. 2003;22:580."},{"key":"2020021219191643500_R199","doi-asserted-by":"crossref","unstructured":"Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med. 1996;124(3):311\u2013315.","DOI":"10.7326\/0003-4819-124-3-199602010-00005"},{"key":"2020021219191643500_R200","unstructured":"Krackhardt AM, Gribben JG. High-dose therapy and stem cell support in chronic lymphocytic leukemia. In: BD Cheson, ed. Chronic Lymphoid Leukemias. Marcel Dekker Inc; 2001:393\u2013415."},{"key":"2020021219191643500_R201","doi-asserted-by":"crossref","unstructured":"Esteve J, Villamor N, Colomer D, et al. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol. 1998;9:167\u2013172.","DOI":"10.1023\/A:1008266505896"},{"key":"2020021219191643500_R202","doi-asserted-by":"crossref","unstructured":"Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747\u20132753.","DOI":"10.1200\/JCO.2003.12.011"},{"key":"2020021219191643500_R203","doi-asserted-by":"crossref","unstructured":"Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003;17:841\u2013848.","DOI":"10.1038\/sj.leu.2402905"},{"key":"2020021219191643500_R204","unstructured":"Khouri I, Munsell M, Yajzi S, et al. Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia: the case for early intervention. Blood. 2000;96:205a."},{"key":"2020021219191643500_R205","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating MJ, Saliba RM, et al. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy2002;4(3):217\u2013221.","DOI":"10.1080\/146532402320219736"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2003\/1\/153\/1713802\/153_175a.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2003\/1\/153\/1713802\/153_175a.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:32:58Z","timestamp":1682605978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2003\/1\/153\/18659\/Biology-and-Treatment-of-Chronic-Lymphocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":205,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2003.1.153","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,1]]}}}